Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension

Next Previous
Trial Profile

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RECOVER; RECOVER-1
  • Sponsors Reviva Pharmaceuticals

Most Recent Events

  • 08 Jan 2026 According to a Reviva Pharmaceuticals media release, the company announced today that clinical biomarker data from the RECOVER Phase 3 clinical trial have been published in the peer-reviewed journal Biological Psychiatry.
  • 13 Nov 2025 According to a Reviva Pharmaceuticals media release, data from the trial were presented at the Central Nervous System (CNS) Summit in Boston, MA, November 2-5, 2025
  • 13 Nov 2025 According to a Reviva Pharmaceuticals media release, company is preparing for a pre-NDA meeting with the Food and Drug Administration (FDA) in the fourth quarter of the year and continue to target a potential NDA submission in the second quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top